Sartorius successfully closed the acquisition of selected life science businesses of Danaher Corporation. The transaction was completed on April 30, 2020, after receiving the required regulatory approvals. “The acquisition of this portfolio is a further milestone for Sartorius. The assets w ... more
Sartorius raises forecast for the full year of 2020
Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group
Based on the strong performance of the Bioprocess Solutions Division in the first half of 2020 as well as on high demand also expected to continue for the rest of the current fiscal year, Sartorius raised its full-year sales and earnings guidance for this division and thus for the entire Group. Management now expects consolidated sales revenue to increase by 22% to 26% (previously 15% to 19%) and the Group’s underlying EBITDA margin to reach around 28.5% (previously about 27.5%). Upward revision of this forecast is partly due to the current coronavirus pandemic as Sartorius products are used for manufacturing both vaccines and antiviral medications.
For the Bioprocess Solutions Division, management now forecasts sales growth of 26% to 30% (previously 17% to 21%) and an underlying EBITDA margin of approximately 31% (previously around 30%). The outlook for Lab Products & Services remains unchanged, with sales revenue expected to grow by 10% to 14% at an underlying EBITDA margin of approximately 20% (all forecasts are based on constant currencies as in the past).
Due to the ongoing pandemic, this guidance is subject to greater uncertainty than usual. In particular, these updated projections are based on the assumptions that logistics chains will continue to be stable and production lines remain in operation.
In the first half of 2020, the Sartorius Group increased its order intake according to preliminary figures by 27.5% in constant currencies. Its sales revenue rose by 17.9% at an underlying EBITDA margin of 27.8%.
Sartorius started off fiscal 2020 dynamically with significant double-digit growth in order intake, sales revenue and earnings. “We are very satisfied overall with our first-quarter results and confident about our business progress in the further course of the year,” commented CEO Dr. Joach ... more
New brand promise, new logo, new colors – Sartorius looks different now. The company has revised its brand look. At the focus of this relaunch is Sartorius’ new brand promise that it summarizes in its new claim: Simplifying Progress. With its products and technologies, the company aims to s ... more
Key Benefits of the Cubis II include: Customizable modularity Choose from among 45 weighing modules, two modern user interfaces, several draft shields, and more than 60 software application for thousands of different possible configurations Choose from our adaptable, preconfigured software ... more
- 1analytica 2020: World’s leading trade fair to be held virtually
- 2analytica 2020: The world’s leading trade fair extends its reach with analytica virtual
- 3Portable, point-of-care COVID-19 test could bypass the lab
- 4Researchers dramatically downsize technology for fingerprinting drugs and other chemicals
- 5Attacking tumours directly on identification
- 6Towards a cell-based interceptive medicine in Europe
- 7Giant nanomachine aids the immune system
- 8A tiny instrument to measure the faintest magnetic fields
- 9Leap forward in the fight against antibiotic resistance
- 10New device can measure toxic lead within minutes